Jennison Associates’s Cymabay Therapeutics CBAY Stock Holding History

Jennison Associates’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,992,711	Closed	-$94.3M	–	651
2023 Q4	$94.3M	Buy	3,992,711 +437,437	+12%	+$7.79M	0.07%	115
2023 Q3	$53M	Buy	3,555,274 +1,883,742	+113%	+$25M	0.05%	168
2023 Q2	$18.3M	Buy	1,671,532 +1,047,869	+168%	+$9.76M	0.02%	328
2023 Q1	$5.44M	Buy	+623,663	New	+$4.99M	0.01%	436
2015 Q3	–	Sell	-858,786	Closed	-$2.31M	–	780
2015 Q2	$2.31M	Sell	858,786 -62,369	-7%	-$256K	﹤0.01%	612
2015 Q1	$6.37M	Sell	921,155 -72,345	-7%	-$695K	0.01%	511
2014 Q4	$9.77M	Sell	993,500 -6,500	-0.7%	-$52.3K	0.01%	485
2014 Q3	$6.84M	Buy	+1,000,000	New	+$6.15M	0.01%	496

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jennison Associates's CBAY Position: Q1 2024 in Review

Jennison Associates sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 3,992,711 shares — an estimated $94.3M sold.

Jennison Associates first reported a position in CBAY in Q3 2014 and held it in 8 quarters. The position peaked at $94.3M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Jennison Associates reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Jennison Associates sold 3,992,711 Cymabay Therapeutics shares in Q1 2024, an estimated $94.3M.
Jennison Associates first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 8 quarters.
Jennison Associates's Cymabay Therapeutics position peaked at $94.3M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Jennison Associates's 13F filing for Q1 2024, filed 2 May 2024.